- Home
- MIRA vs HBIO Comparison
MIRA vs HBIO Comparison
Compare MIRA & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRA | HBIO |
|---|---|---|
| Founded | 2020 | 1901 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.7M | 33.8M |
| IPO Year | 2023 | 2000 |
Fundamental Metrics
Financial Performance| Metric | MIRA | HBIO |
|---|---|---|
| Price | $1.50 | $0.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 251.1K | ★ 598.2K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $87,371,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.73 | $0.28 |
| 52 Week High | $2.45 | $2.28 |
Technical Indicators
Market Signals| Indicator | MIRA | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.32 | 44.94 |
| Support Level | $1.52 | $0.71 |
| Resistance Level | $1.69 | $0.80 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 24.00 | 6.90 |
Price Performance
Historical ComparisonAbout MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.